PTO/SB/05 (05-03)

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to re

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.		1861.1520001/JMC/RHD					
First Inv	ventor	Qun Sun					
Title	le Aryl Substituted Benzimidazoles and Their Use as Sodium Channel Blockers						

Submit an original, and a duplicate for fee processing	Commissioner for Patents ADDRESS TO: Mail Stop Patent Application P.O. Box 1450 Alexandria VA 22313-1450									
10.	(Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies); or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS									
a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76. 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant in form PTO/SB3/55 or its equivalent. 17. Other: Authorization under 37 C.F.R. § 1.136(a)(3) Other: The name of the assignee is: Euro-Celtique S.A. 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 C.F.R. § 1.136(a)(3) Continuation Divisional Continuation: Examiner For CONTINUINO OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation generalized by the requisited application parts.	10. 37 CFR 3.73(b) Statement Power of Attorney (when there is an assignee)									
b.	English Translation Document (if applicable)									
b. Copy from a prior application (37 CFR 1.63(d))	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations									
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76. 6. Other: Authorization under 37 C.F.R. § 1.136(a)(3) Other: The name of the assignee is: Euro-Celtique S.A. 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box considered a part of the disclosure of the accompanying continuation or divisional application parts.	CFR 1.63(d))									
named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b). Application Data Sheet. See 37 CFR 1.76. Application Data Sheet. See 37 CFR 1.76. 16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant m form PTO/SB/35 or its equivalent. 17. Other: Authorization under 37 C.F.R. § 1.136(a)(3) Other: The name of the assignee is: Euro-Celtique S.A. 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No: / Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation continuation parts.	<u> </u>									
Application Data Sheet. See 37 CFR 1.76. 16.	on, see 37 CFR §§ 15. Certified Copy of Priority Document(s)									
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No:/	0.									
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No:/	Others Authorization under 27 C.F.B. \$ 1.126(a)(2)									
or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-Part (CIP) of prior application No:/ Prior application information: Examiner Group/Art Unit: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation continuation parts. 19. CORRESPONDENCE ADDRESS	Other: The name of the assignee is: Euro-Celtique S.A.									
	or in an Application Data Sheet under 37 CFR 1.76:									
Customer Number 26111 or Correspondence address below	19. CORRESPONDENCE ADDRESS									
	Customer Number 26111									
NAME STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	PEIN & FOX P.L.L.C.									
Attorneys at Law ADDRESS										
CITY STATE ZIP CODE	STATE ZIP CODE									
COUNTRY TELEPHONE FAX	TELEPHONE FAX									
NAME (Print/Type) John M Covert Registration No. (Attorney/Agent) 38,759										
NAME (Print/Type) John M Covert (Registration No. (Attorney/Agent) 38,759 SIGNATURE Date July 31, 2003										

This collection of information frequired by 37 CFR 1.53 (b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

SKGF Rev 5/16/03 mac SKGF_DC1:161546.1

Under the Paperwork Reduction Act of 1995, no persons

C	_
-	-
_	_
C	۰
-	-
-	_
	Š
-	_

FEE TRANSMITTAL for EV 2000

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

s are required to respond to a	a collection of information unless it displays a valid OMB control number
	Complete if Known
Application Number	To B Assigned
Filing Date	Herewith (July 31, 2003)
First Named Inventor	Qun Sun
Examiner Name	To Be Assigned
Art Unit	To Be Assigned
Attorney Docket No.	1861.1520001/JMC/RHD

TELESTAL AMOUNT OF PATMENT (\$)1,000.00					1861.15200	O I/JIVIC/	KHD		
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)								
Check Credit card Money Order Other** None ** Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.		3. ADDITIONAL FEES Large Entity Small Entity							
calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036. Deposit Account	Fee Code	Fee Fee	Fee		Fee Description		Fee Paid		
Deposit Account Number 19-0036					·				
Deposit Account Name: Sterne, Kessler, Goldstein & Fox P.L.L.C.	1051	130	2051	65	Surcharge - late filing fe	ee or oath			
The Commissioner is authorized to: (check all that apply)	1502	50	2052	25	Surcharge-late provision sheet	late provisional filing fee or cover			
☐ Charge fee(s) indicated below ☐ Credit any over payments	1053	130	1053	130	Non-English specification	n-English specification			
☐ Charge any additional fee(s) during the pendency of this application	1812	2,520	1812	2,520	For filing a request for e	ex parte reex	amination		
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1804	920*	1804	920*	Requesting publication action	to Examiner			
above-hadrianed deposit decours.	1805	1,840*	1805	1,840*	Requesting publication action	of SIR after	Examiner		
	1251	110	2251	55	Extension for reply with	,			
	1252	410	2252	205	Extension for reply with	onth			
FEE CALCULATION	1253	930	2253	465	Extension for reply with	tension for reply within third month			
1. BASIC FILING FEE	1254	1,450	2254	725	Extension for reply with	sion for reply within fourth month			
Large Entity Small Entity	1255	1,970	2255	985	Extension for reply with	nin fifth montl	n		
Fee Fee Fee Fee Fee Description Fee Paid	1401	320	2401	160	Notice of Appeal				
Code (\$) Code (\$) 1001 750 2001 375 Utility filing fee 750.00	1402	320	2402	160	Filing a brief in support	of an appea			
1002 330 2002 165 Design filing fee	1403	280	2403	140	Request for oral hearing				
1003 520 2003 260 Plant filing fee	1451	1,510	1451	1,510	Petition to institute a pu	ıblic use pro	ceeding		
1004 750 2004 375 Reissue filing fee	1452	110	2452	55	Petition to revive - una	voidable			
1105 160 2005 80 Provisional filing fee	1453	1,300	2453	650	Petition to revive - unin	to revive - unintentional			
	1501	1,300	2501	650	Utility issue fee (or reis	sue)			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1502	470	2502	235	Design issue fee				
Fee from Extra below Fee Paid	1503	630	2503	315	Plant issue fee				
Total Claims 62 - 20** = 42 X 18 = 756.00	1460	130	1460	130	Petitions to the Commis	ssioner			
Indep. Claims _ 1 3** = _0 _ X = _0		50	1807	50	Processing fee under 3	(g)			
	1806	180	1806	180	Submission of Informat	tion Disclosu	re Stmt		
Large Entity Small Entity Fee Fee Fee Fee Description Code (\$) Code (\$)		40	8021	40	Recording each patent assignment per property (times number of properties)				
1202 18 2202 9 Claims in excess of 20	1809	750	2809	375	Filing a submission after final rejection (37 CFR				
1201 84 2201 42 Independent claims in excess of 3 1203 280 2203 140 Multiple dependent claim, if not paid	1010	750	2810	275	1.129(a))				
1204 84 2204 42 **Reissue independent claims	1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))				
over original patent	1801	750	2801	375	Request for Continued	Examination	(RCE)		
1205 18 2205 9 **Reissue claims in excess of 20	1802	02 900 1802	1802	900	Request for expedited application	examination	of a design		
and over original patent SUBTOTAL (2) (\$)756.00	Other	application Other fee (specify)					L		
**or number previously paid, if greater; For Reissue, see above		* Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)0					(3) (\$)0		
SUBMITTED BY						Complete (if	applicable)		
Name (Print/Type) John M. Covert	Regis (Attor	tration N ney/Ager	o. nt)		38,759	Telephone			
Signature Atha M. Com						Date	July 31, 2003		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.16/ This collection is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.16/ This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, O.P. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michaele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherston Michael V. Messinger

Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro' Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weave Kendrick P. Patterson Vincent L. Capuano Albert J. Fasulo 11* Eldora Ellison Floyd Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston*

Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Christine M. Lhuller Rae Lynn Prengaman Jane Shershenovich* Lawrence J. Carroll* George S. Bardmesser Daniel A. Klein* Rodney G. Maze Jason D. Eisenberg Michael A. Specht* Andrea J. Kamage Tracy I. Muller* Tracy L. Muller Jon E. Wright*

LuAnne M. Yuricek* Registered Patent Agents • Karen R. Markowicz

Karen R. Martowicz Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby L. Longsworth Marthew J. Dowd Aaron L. Schwartz Angelique G. Uy Mary B. Tung Katrina Y. Per Bryan L. Skelton Robert A. Schwartzman John J. Figueroa Immothy A. Doyle Jennifer R. Mahalingappa

Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford

<u>Of Counsel</u> Kenneth C. Bass III Lisa A. Dunner Evan R. Smith

*Admitted only in Maryland * Admitted only in Virginia •Practice Limited to Federal Agencies

July 31, 2003

WRITER'S DIRECT NUMBER: (202) 772-8673 **INTERNET ADDRESS:** JCOVERT@SKGF.COM

Mail Stop Patent Application

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To Be Assigned; Filed: Herewith (July 31, 2003)

Aryl Substituted Benzimidazoles and Their Use as Sodium Channel For:

Blockers

Inventors: Sun et al.

Our Ref: 1861.1520001/JMC/RHD

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. PTO Fee Transmittal (Form PTO/SB/17);
- 2. PTO Utility Patent Application Transmittal (Form PTO/SB/05);
- 3. U.S. Utility Patent Application entitled:

Aryl Substituted Benzimidazoles and Their Use as Sodium Channel Blockers

and naming as inventors:

Oun SUN Xiaoming ZHOU Donald J. KYLE

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents July 31, 2003 Page 2

the application consisting of:

- a. An Application Data Sheet (37 C.F.R. § 1.76);
- b. A specification containing:
 - i. 27 pages of description prior to the claims;
 - ii. 12 pages of claims (62 claims);
 - iii. a one (1) page abstract;
- 4. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3);
- 5. Form PTO-2038 Credit Card Payment Form for \$1,506.00 to cover: \$750.00 Filing fee for patent application; and \$756.00 Fee for excess claims; and
- 6. Two (2) return postcards.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

John M. Covert

Attorney for Applicants Registration No. 38,759

JMC/RHD:cpn Enclosures

SKGF_DC1:161537.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Sun et al.

Appl. No. To Be Assigned

Filed: Herewith (July 31, 2003)

Aryl Substituted Benzimidazoles

and Their Use as Sodium Channel

Blockers

Confirmation No. To Be Assigned

Art Unit: To Be Assigned

Examiner: To Be Assigned

Atty. Docket: 1861.1520001/JMC/RHD

Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

forney for Applicants egistration No. 38,759

Date: July 31, 2003

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

::ODMA\MHODMA\SKGF_DC1;161579;1